JP Morgan Chase
SGMT icon

JP Morgan Chase’s Sagimet Biosciences SGMT Stock Holding History

JP Morgan Chase’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.5K Sell
2,318
-170
-7% -$947 ﹤0.01% 6729
2025
Q4 		$14.7K Buy
2,488
+2,390
+2,439% +$17.2K ﹤0.01% 6580
2025
Q3 		$672 Hold
98
– – ﹤0.01% 7031
2025
Q2 		$747 Hold
98
– – ﹤0.01% 6655
2025
Q1 		$319 Sell
98
-47,966
-100% -$201K ﹤0.01% 6746
2024
Q4 		$216K Sell
48,064
-23,953
-33% -$121K ﹤0.01% 5441
2024
Q3 		$199K Buy
72,017
+28,690
+66% +$88.4K ﹤0.01% 5406
2024
Q2 		$148K Sell
43,327
-1,079,980
-96% -$4.95M ﹤0.01% 5317
2024
Q1 		$6.09M Buy
1,123,307
+1,119,766
+31,623% +$8.04M ﹤0.01% 2925
2023
Q4 		$19.2K Hold
3,541
– – ﹤0.01% 6260
2023
Q3 		$31.2K Buy
+3,541
New +$47.1K ﹤0.01% 5953

Other funds holding SGMT

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase's SGMT Position: Q1 2026 in Review

JP Morgan Chase reduced its Sagimet Biosciences (SGMT) stake by 6.8% in Q1 2026, selling an estimated $947 and leaving 2,318 shares worth $10.5K. The position accounts for ﹤0.01% of the portfolio, ranked #6729.

JP Morgan Chase first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. The position peaked at $6.09M in Q1 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

  • JP Morgan Chase held 2,318 shares of Sagimet Biosciences worth $10.5K as of Q1 2026.
  • JP Morgan Chase sold 170 Sagimet Biosciences shares in Q1 2026, an estimated $947.
  • Sagimet Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #6729 holding.
  • JP Morgan Chase first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • JP Morgan Chase's Sagimet Biosciences position peaked at $6.09M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.